BeiGene
BGNE
$148.85
Share price
-3.50%
Change (1 day)
-33.39%
Change (1 year)
Categories
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.
BeiGene (BGNE) - Cash on Hand
Cash on Hand as of March 2024 : $2.79 B
According to BeiGene
's latest financial reports the company has $2.79 B in cash and cash equivalents.
A company’s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
BeiGene - Cash on Hand chart (from 2014 to 2024)
Cash on Hand by year
| Year | Cash on Hand | Change |
|---|---|---|
| 2023-12-31 | $3.17 B | -30% |
| 2022-12-31 | $4.53 B | -31.47% |
| 2021-12-31 | $6.61 B | 42.29% |
| 2020-12-31 | $4.65 B | 373.24% |
| 2019-12-31 | $0.98 B | -44.83% |
| 2018-12-31 | $1.78 B | 112.71% |
| 2017-12-31 | $0.83 B | 127.48% |
| 2016-12-31 | $0.36 B | 266.39% |
| 2015-12-31 | $0.10 B | 126.35% |
| 2014-12-31 | $44.39 M | 1030.79% |
| 2013-12-31 | $3.92 M |
Cash on Hand for similar companies or competitors
| Company | Cash on Hand | differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | $75.63 M | -97.29% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | $16.39 M | -99.41% | 🇺🇸 USA |